Arthrosi Therapeutics - About the company
Arthrosi Therapeutics is an acquired company based in Irvine (United States), founded in 2017. It operates as a Developer of therapeutics for gout, chronic kidney diseases, and oncology. Arthrosi Therapeutics has raised $293M in funding from Prime Eight Capital and Guangrun Health Industry, with last known valuation of $*****. The company has 3480 active competitors, including 1168 funded and 814 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.
Company Details
Developer of therapeutics for gout, chronic kidney diseases, and oncology. The company's proprietary drug candidate includes AR882 which is used to decrease the level of uric acid in gout patients. It works by inhibiting urate transporter 1 (URAT1), an influx transporter protein present in kidneys.
- Website
- arthrosi.com
- Email ID
- *****@arthrosi.com
Key Metrics
Founded Year
2017
Location
Irvine, United States
Stage
Acquired
Total Funding
$293M in 8 rounds
Latest Funding Round
Last Known Valuation
$***** as on Dec 14, 2025
Investors
Ranked
136th among 3480 active competitors
Employee Count
30 as on Aug 31, 2026
Similar Companies
Exit Details
Acquired by Swedish Orphan Biovitrum (Dec 14, 2025)
Legal entities associated with Arthrosi Therapeutics
Arthrosi Therapeutics is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
Arthrosi Therapeutics, Inc CIN: 821310589 , United States, Active | Dec 31, 2016 | - | 26 (As on Dec 31, 2024) | - |
Arthrosi Therapeutics's acquisition details
Arthrosi Therapeutics got acquired by Swedish Orphan Biovitrum on Dec 14, 2025 at an acquisition amount of $*****.
Click here to take a look at Arthrosi Therapeutics's acquisition in detail
Sign up to download Arthrosi Therapeutics' company profile
Arthrosi Therapeutics's funding and investors
Arthrosi Therapeutics has raised a total funding of $293M over 8 rounds. Its first funding round was on Jun 29, 2018. Its latest funding round was a Series E round on Jun 06, 2025 for $*****. 5 investors participated in its latest round. Arthrosi Therapeutics has 13 institutional investors.
Here is the list of recent funding rounds of Arthrosi Therapeutics:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jun 06, 2025 | 8827941 | Series E | 3213219 | 8343031 | 8254431 | 3565509 |
Jul 12, 2023 | 8288119 | Series D | 4905138 | 6287524 | 6610453 | |
Mar 02, 2023 | 7849473 | Series B | 4500262 | 2212362 | 6921019 | 3240287 |
Access funding benchmarks and valuations. Sign up today!View details of Arthrosi Therapeutics's funding rounds and investors
Arthrosi Therapeutics' founders and board of directors
Founder? Claim ProfileArthrosi Therapeutics' employee count trend
Arthrosi Therapeutics has 30 employees as of Aug 26. Here is Arthrosi Therapeutics's employee count trend over the years:
Uncover Arthrosi Therapeutics' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Arthrosi Therapeutics's Competitors and alternates
Top competitors of Arthrosi Therapeutics include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Arthrosi Therapeutics, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 81/100 | |
2nd |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 81/100 | |
3rd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 74/100 | |
4th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 73/100 | |
5th | Senti Bio 2016, San Francisco (United States), Public | Developer of cell and gene therapies for patients living with incurable diseases | $158M | 72/100 | |
6th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
7th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
8th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 72/100 | ||
9th |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 72/100 | |
10th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
136th |  Arthrosi Therapeutics 2017, Irvine (United States), Acquired | Developer of therapeutics for gout, chronic kidney diseases, and oncology | $293M | 61/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Arthrosi Therapeutics's competitors? Click here to see the top ones
Arthrosi Therapeutics's Investments and acquisitions
Arthrosi Therapeutics has made no investments or acquisitions yet.
Reports related to Arthrosi Therapeutics
Here is the latest report on Arthrosi Therapeutics's sector:
News related to Arthrosi Therapeutics
Filter this listMedia has covered Arthrosi Therapeutics for a total of 5 events in the last 1 year.
•
Sobi Completes Acquisition of Arthrosi TherapeuticsFinancial Times•Feb 09, 2026•Arthrosi Therapeutics, Swedish Orphan Biovitrum
•
•
•
•
Arthrosi Therapeutics Secures $153M for Gout Drug DevelopmentBioPharmaDive•Oct 09, 2025•Arthrosi Therapeutics, Eisai, AstraZeneca, Amgen and 6 others
•
•
•
•
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Arthrosi Therapeutics
Explore our recently published companies
- Face to Face Art - United States based, 1993 founded, Unfunded company
- Buffalo Commons Charter School - Buffalo based, Unfunded company
- Neovia Group - Vannes based, 1954 founded, Acquired company
- MiningStore - United States based, 2015 founded, Unfunded company
- Hanafusa Honey - Japan based, Unfunded company
- Majuro Water & Sewer Company - Marshall Islands based, 1989 founded, Funding Raised company
